

**Onondaga County**

Shepard Settlement Cemetery, Stump & Foster Rds, Shepard Settlement, 10000938

**Orange County**

Beakes, John G., House, 134 W Main St, Middletown, 10000939

Grace Episcopal Church, 58 N St, Middletown, 10000945

Mapes, Mortimer L., House & Seward Homestead, 35 N Main St, Florida, 10000942

**St. Lawrence County**

Fort la Presentation Site, Address Restricted, Ogdensburg, 10000944

**Steuben County**

Gold Seal Winery, West Lake Rd, Hammondsport, 10000946

**Sullivan County**

Greenfield Preparative Meeting House, NY 55 at Denman Mt Rd, Grahamsville, 10000956

**Washington County**

McNish, Alexander, House, 194 CR 30, New York, 10000959

Simonds, L.C., Adirondack Cabin, 130 Cat Den Rd, Clemons, 10000941

**SOUTH DAKOTA**

**Brookings County**

Hall, John L., House, 121 Samara Ave, Volga, 10000955

Lockhart House, 1001 6th Ave, Brookings, 10000954

**Davison County**

Henline, Ellis and Roberta Farmstead, 39987 252nd St, Mount Vernon, 10000950

**Faulk County**

Edgerton, Dr. William, House, 308 Tenth Ave S, Faulkton, 10000951

**Tripp County**

Wewela Hall, Lots 3 and 4, Block 34, Government Townsite of Wewela, Wewela, 10000952

**Walworth County**

Molstad Lake Park, (Federal Relief Construction in South Dakota MPS) 1 3/4 mi N of HWY 12 on 293rd Ave, Glenham, 10000953

**TENNESSEE**

**Anderson County**

Daugherty Furniture Building, 307 N Main St, Clinton, 10000936

**Davidson County**

Municipal Public Works Garage Industrial District, 33 Peabody St, Nashville, 10000949

**Henderson County**

Doe Creek School, Doe Creek Rd, approx 1/2 mi N of Dyer Rd, Sardis, 10000935

**Knox County**

Lebanon in the Forks Cemetery, (Knoxville and Knox County MPS) Asbury Rd N of Norfolk Southern Railroad, Knoxville, 10000934

**TEXAS**

**Harris County**

Near Northside Historic District, Roughly bounded by Little White Oak Bayou on the N; Hogan on the S; I-45 On the W and the block between N Main and Keene Houston, 10000960

**Hays County**

Lane, James C., House, (Rural Properties of Hays County, Texas MPS) 306 Wimberley Square, Wimberley, 10000961

**Hunt County**

Washington Hotel, 2612 Washington St, Greenville, 10000962

**Uvalde County**

Nicolas Street School, 332 Nicolas St, Uvalde, 10000963

**Related Action: Request for REMOVAL has been made for the following resources:**

**COLORADO**

**Larimer County**

Big Thompson River Bridge I, US 34 at milepost 65.53 Larimer, 02001144

Big Thompson River Bridge II, US 34 at milepost 66.22 Larimer, 02001141

**KENTUCKY**

**Jefferson County**

Bloedner, August, Monument, Cave Hill Cemetery, jct. of Payne St. & Lexington Rd., Louisville, 97000688

[FR Doc. 2010-30312 Filed 12-2-10; 8:45 am]

**BILLING CODE 4312-51-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on October 6, 2010, Mylan Technologies, Inc., 110 Lake Street, Saint Albans, Vermont 05478, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Methylphenidate (1724) .....	II

Drug	Schedule
Fentanyl (9801) .....	II

The company plans to import the listed controlled substances in finished dosage form (FDF) from foreign sources for analytical testing and clinical trials in which the foreign FDF will be compared to the company's own domestically-manufactured FDF. This analysis is required to allow the company to export domestically-manufactured FDF to foreign markets.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 3, 2011.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745-46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: November 19, 2010.

**Joseph T. Rannazzisi,**

*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010-30336 Filed 12-2-10; 8:45 am]

**BILLING CODE 4410-09-P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing

a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on June 4, 2010, Clinical Supplies Management, Inc., 342 42nd Street South, Fargo, North Dakota 58103, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Sufentanil (9740), a basic class of controlled substance listed in schedule II.

The company plans to import the listed controlled substance with the sole purpose of packaging, labeling, and distributing to customers which are qualified clinical sites conducting clinical trials under the auspices of an FDA-approved clinical study.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 3, 2011. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the **Federal Register** on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: November 18, 2010.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010–30344 Filed 12–2–10; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on July 28, 2010, Fisher Clinical Services, Inc., 7554 Schantz Road, Allentown, Pennsylvania 18106, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedule II:

Drug	Schedule
Noroxymorphone (9668) .....	II
Tapentadol (9780) .....	II

The company plans to import the listed substances for analytical research and clinical trials.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrisette Drive, Springfield, Virginia 22152; and must be filed no later than January 3, 2011.

This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the

**Federal Register** on September 23, 1975, (40 FR 43745–46), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied.

Dated: November 18, 2010.

**Joseph T. Rannazzisi,**  
*Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.*

[FR Doc. 2010–30348 Filed 12–2–10; 8:45 am]

**BILLING CODE 4410–09–P**

**DEPARTMENT OF JUSTICE**

**Drug Enforcement Administration**

**Importer of Controlled Substances; Notice of Application**

Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing.

Therefore, in accordance with 21 CFR 1301.34(a), this is notice that on September 13, 2010, Chattem Chemicals, Inc., 3801 St. Elmo Avenue, Building 18, Chattanooga, Tennessee 37409, made application by letter to the Drug Enforcement Administration (DEA) to be registered as an importer of 4-Anilino-N-Phenethyl-4-Piperidine (ANPP) (8333), a basic class of controlled substance listed in schedule II.

The company plans to import this controlled substance in bulk for use in the manufacture of another controlled substance.

Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration, and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43, and in such form as prescribed by 21 CFR 1316.47.

Any such comments or objections should be addressed, in quintuplicate,